Treatment of type I ROP with intravitreal bevacizumab or laser photocoagulation according to retinal zone

Mueller, Brett H.; Salchow, Daniel J.; Waffenschmidt, E; Joussen, Antonia M.; Schmalisch, Gerd; Czernik, Ch; Bührer, C. H.; Schunk, K.; Girschick, Hermann; Winterhalter, Sibylle

doi:10.1136/bjophthalmol-2016-308375

Cited by 44 publications

(40 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Retinopathy of prematurity recurrences requiring an additional treatment after IVR monotherapy were defined as the reappearance of EFP in eyes after an initial resolution of acute-phase ROP. 5,21 Return of plus disease was not necessarily required, but an important sign showing the activity of recurrence. Recurrences were retreated with diode laser ablation to the avascular retina.…”

Section: Recurrence Requiring Retreatmentmentioning

confidence: 99%

Recurrence of Retinopathy of Prematurity After Intravitreal Ranibizumab Monotherapy: Timing and Risk Factors

Lyu

Zhang

Chen

et al. 2017

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

show abstract

Section: Recurrence Requiring Retreatmentmentioning

confidence: 99%

Recurrence of Retinopathy of Prematurity After Intravitreal Ranibizumab Monotherapy: Timing and Risk Factors

Lyu

Zhang

Chen

et al. 2017

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

show abstract

“…Diese Aufnahmen sind nicht nur in der primären Diagnostik relevant, sondern auch in der Verlaufsbeurteilung nach Therapie. Mittels Angiografie können periphere ischämische Netzhautareale sichtbar und in gewissen Grenzen auch quantifiziert werden [3] [6,7]. Dennoch verbleiben häufig periphere Netzhautanteile scheinbar avaskulär, ein Befund, den man toleriert, aber aus bislang ungeklärter klinischer Relevanz und vor dem Hintergrund möglicher Spätrezidive mit Netzhautablösung in regelmäßigen Abständen kontrolliert [8,9].…”

Section: Allgemeine Und Technische üBerlegungenunclassified

Ultraweitwinkel-Fundusfotografie und -angiografie in der Differenzialdiagnose und zur Therapieplanung bei peripheren vaskulären Netzhauterkrankungen

Joussen

Brockmann

Urban

et al. 2018

Klin Monatsbl Augenheilkd

View full text Add to dashboard Cite

Investigation of vascular diseases of the peripheral retina requires imaging procedures that allow a comprehensive view of the periphery, as well as reproducible pictures. In particular, ultra-wide field fluorescence angiography facilitates diagnosis, therapeutic decisions and follow-up examinations. While vasculopathies such as Coats disease and familiar exudative vitreoretinopathy are diagnosed within the first and second decade of life, patients' compliance during fundus imaging is typically reduced within this age range. Compared to the repeated imaging procedures for composite formation, ultra-wide field imaging has significantly reduced recording time. Nevertheless, current imaging systems are not able to map the entire retina in scaled proportions. Therefore, the imaging frame must be guided by patients' gaze onto the affected retinal area. Moreover, the medical photographer must be aware of the clinical setting and the region of interest. Hence, previous detailed funduscopy by trained ophthalmologists will remain indispensable.

show abstract

“…In the past few decades, laser photocoagulation has been frequently used to treat ROP [ 3 – 6 ]. The application of laser treatment remains controversial because of its side-effects, including visual field loss, high myopia and retinal destruction [ 7 – 9 ]. Although the pathogenesis of ROP is incompletely understood, vascular endothelial growth factor (VEGF) has been considered to be one of the key mechanisms in vasculogenesis and angiogenesis.…”

Section: Introductionmentioning

confidence: 99%

Comparison of efficacy between anti-vascular endothelial growth factor (VEGF) and laser treatment in Type-1 and threshold retinopathy of prematurity (ROP)

Zhang

Liao

et al. 2018

BMC Ophthalmol

View full text Add to dashboard Cite

BackgroundRetinopathy of Prematurity (ROP) is one of the most common causes of childhood blindness worldwide. Comparisons of anti-VEGF and laser treatments in ROP are relatively lacking, and the data are scattered and limited. The objective of this meta-analysis is to compare the efficacy of both treatments in type-1 and threshold ROP.MethodsA comprehensive literature search on ROP treatment was conducted using PubMed and Embase up to March 2017 in all languages. Major evaluation indexes were extracted from the included studies by two authors. The fixed-effects and random-effects models were used to measure the pooled estimates. The test of heterogeneity was performed using the Q statistic.ResultsTen studies were included in this meta-analysis. Retreatment incidence was significantly increased for anti-VEGF (OR 2.52; 95% CI 1.37 to 4.66; P = 0.003) compared to the laser treatment, while the incidences of eye complications (OR 0.29; 95% CI 0.10 to 0.82; P = 0.02) and myopia were significantly decreased with anti-VEGF compared to the laser treatment. However, there was no difference in the recurrence incidence (OR 1.86; 95% CI 0.37 to 9.40; P = 0.45) and time between treatment and retreatment (WMD 7.54 weeks; 95% CI 2.00 to 17.08; P = 0.12).ConclusionThis meta-analysis indicates that laser treatment may be more efficacious than anti-VEGF treatment. However, the results of this meta-analysis also suggest that laser treatment may cause more eye complications and increase myopia. Large-scale prospective RCTs should be performed to assess the efficacy and safety of anti-VEGF versus laser treatment in the future.Electronic supplementary materialThe online version of this article (10.1186/s12886-018-0685-6) contains supplementary material, which is available to authorized users.

show abstract

Treatment of type I ROP with intravitreal bevacizumab or laser photocoagulation according to retinal zone

Cited by 44 publications

References 23 publications

Recurrence of Retinopathy of Prematurity After Intravitreal Ranibizumab Monotherapy: Timing and Risk Factors

Recurrence of Retinopathy of Prematurity After Intravitreal Ranibizumab Monotherapy: Timing and Risk Factors

Ultraweitwinkel-Fundusfotografie und -angiografie in der Differenzialdiagnose und zur Therapieplanung bei peripheren vaskulären Netzhauterkrankungen

Comparison of efficacy between anti-vascular endothelial growth factor (VEGF) and laser treatment in Type-1 and threshold retinopathy of prematurity (ROP)

Contact Info

Product

Resources

About